In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Ajovy (Teva); TEV-48125 (Teva)
- INDICATIONS: Migraine in adults
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist, Monoclonal antibody
- HALF-LIFE: ~31 days
- FDA APPROVAL DATE: 09/14/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no adequate data on the developmental risk associated with the use of fremanexumab in pregnant women. The long half life of fremanezumab should be a consideration for women who are pregnant or plan to become pregnant while using fremanezumab.
- See adverse reactions attributed to class:
Contraindicated in patients with serious hypersensitivity to fremanezumab or to any of the excipients.
Fremanezumab-Vfrm is biosimilar to Fremanezumab.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fremanezumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/23/2024
